Licensing opportunities
Università della Svizzera italiana (USI) and its affiliated institutes, the Institute for Research in Biomedicine (IRB) and the Institute of Oncology Research (IOR), actively promote the commercial potential of their innovative research by granting licences.
We invite companies interested in accessing cutting-edge technologies and patents to explore the opportunities listed below.
Università della Svizzera italiana (USI) - Technology Offers
PRIVACY-PRESERVING DATA HIDING FOR PROXIMITY MATCHING AND CONTACT TRACING
PRIVACY-PRESERVING DATA HIDING FOR PROXIMITY MATCHING AND CONTACT TRACING
CRYPTO-OPTIMIZED RECONFIGURABLE LOGIC CELL AND SLICE FOR SECURE, EFFICIENT CRYPTOGRAPHY ACCELERATION
CRYPTO-OPTIMIZED RECONFIGURABLE LOGIC CELL AND SLICE FOR SECURE, EFFICIENT CRYPTOGRAPHY ACCELERATION
Institute for Research in Biomedicine (IRB) - Technology Offers
HUMAN MONOCLONAL ANTIBODIES AGAINST WEST NILE VIRUS AND RELATED ORTHOFLAVIVIRUSES
HUMAN MONOCLONAL ANTIBODIES AGAINST WEST NILE VIRUS AND RELATED ORTHOFLAVIVIRUSES
HUMAN MONOCLONAL ANTIBODIES AGAINST RUBIVIRUSES (RUBELLA, RUSTRELA AND RUHUGU)
HUMAN MONOCLONAL ANTIBODIES AGAINST RUBIVIRUSES (RUBELLA, RUSTRELA AND RUHUGU)
ANTIBODIES AGAINST CHEMOKINES FOR DIAGNOSTIC AND THERAPY
ANTIBODIES AGAINST CHEMOKINES FOR DIAGNOSTIC AND THERAPY
ENGINEERING B LYMPHOCYTES VIA ENDOGENOUS AID FOR CUSTOMIZED ANTIBODY PRODUCTION
ENGINEERING B LYMPHOCYTES VIA ENDOGENOUS AID FOR CUSTOMIZED ANTIBODY PRODUCTION
PEPTIDE INHIBITORS TARGETING THE CXCL-12/HMGB1 INTERACTION AND USES THEREOF
PEPTIDE INHIBITORS TARGETING THE CXCL-12/HMGB1 INTERACTION AND USES THEREOF
Institute of Oncology Research (IOR) - Technology Offers
MONOSPECIFIC AND BISPECIFIC ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING NECTIN2 (CD112) AND PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOR THE TREATMENT OF PROSTATE CANCER
MONOSPECIFIC AND BISPECIFIC ANTIBODIES AND ANTIBODY-DRUG CONJUGATES TARGETING NECTIN2 (CD112) AND PROSTATE-SPECIFIC MEMBRANE ANTIGEN FOR THE TREATMENT OF PROSTATE CANCER
TRIM24 DEGRADERS TO TREAT PROSTATE CANCER AND DELAY RESISTANCE
TRIM24 DEGRADERS TO TREAT PROSTATE CANCER AND DELAY RESISTANCE
SMALL-MOLECULE FOXA1/FOXA2 INHIBITORS FOR ONCOLOGY (PROSTATE, BREAST, GASTRIC, NEUROENDOCRINE & LIVER CANCERS)
SMALL-MOLECULE FOXA1/FOXA2 INHIBITORS FOR ONCOLOGY (PROSTATE, BREAST, GASTRIC, NEUROENDOCRINE & LIVER CANCERS)
AFFINITY REAGENTS TARGETING HERV-K ENVELOPE FOR LYMPHOMA THERAPY AND DIAGNOSTICS
AFFINITY REAGENTS TARGETING HERV-K ENVELOPE FOR LYMPHOMA THERAPY AND DIAGNOSTICS
ANTIBODIES TARGETING METHYLATED ERG FOR PRECISION TREATMENT AND DIAGNOSIS OF ERG-POSITIVE PROSTATE CANCER
ANTIBODIES TARGETING METHYLATED ERG FOR PRECISION TREATMENT AND DIAGNOSIS OF ERG-POSITIVE PROSTATE CANCER
GENETIC REPROGRAMMING BY RE-EXPRESSION OF ESE3/EHF FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
GENETIC REPROGRAMMING BY RE-EXPRESSION OF ESE3/EHF FOR THE TREATMENT OF ADVANCED PROSTATE CANCER